文献速递淋巴瘤

PET/CT在外周T细胞淋巴瘤中的作用:英国NCRI二期CHEMO-T试验PET/CT子研究结果

The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.
PubMed 文献 · Br J Haematol · 2025-05-26

英国国家癌症研究所(NCRI)二期随机CHEMO-T试验比较CHOP与GEM-P方案治疗初治外周T细胞淋巴瘤(PTCL),PET/CT作用为关键次要终点。基线PET/CT使43%患者分期改变,治疗结束时PET/CT阴性者2年无进展生存55%优于阳性者29%(HR 0.45,p=0.021)。

要点

  • 基线PET/CT使43%的PTCL患者疾病分期改变,25%发现额外结外部位。
  • 治疗结束时PET/CT阴性较阳性与更优的2年PFS相关(55% vs 29%,HR 0.45)。
  • 作者认为PET/CT应作为PTCL管理的标准治疗组成部分。

核心结论

  • 研究提示PET/CT应作为外周T细胞淋巴瘤管理的标准治疗组成部分。

研究设计与样本

  • 英国国家癌症研究所(NCRI)二期随机CHEMO-T试验比较CHOP与GEM-P方案治疗初治外周T细胞淋巴瘤(PTCL),PET/CT作用为关键次要终点。
  • 所有患者入组时和治疗结束时均要求行PET/CT、增强CT(CECT)和骨髓活检(BMB)。
  • 基线PET/CT数据可获取82/84例。

主要发现

  • 98%(80/82)患者为FDG高摄取疾病。
  • 基线PET/CT较CECT使43%患者疾病分期改变,并在25%患者中发现额外结外部位(最常见为骨髓/骨,n=7)。
  • 基线PET/CT与BMB对骨髓受累的符合率为72.6%,n=20例结果不一致;10例活检证实的骨髓浸润患者PET/CT骨髓阴性;基线PET/CT在BMB阴性患者中检出骨髓受累n=10,主要为局灶性摄取(7/10)。
  • 治疗结束时PET/CT阴性较阳性与更优的2年无进展生存(PFS)相关:55%(95%CI:38%-70%)vs 29%(95%CI:12%-48%),HR 0.45(95%CI:0.23-0.88),p=0.021,且保持独立预后意义。

临床怎么用

  • 作者认为PET/CT应作为外周T细胞淋巴瘤管理的标准治疗组成部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The UK National Cancer Research Institute (NCRI) phase 2 randomised CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T) trial compared the regimens of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) and gemcitabine, cisplatin and methylprednisolone (GEM-P) in treatment-naïve patients with peripheral T-cell lymphoma (PTCL). Evaluation of the role of positron emission tomography/computed tomography (PET/CT) was a key secondary end-point. All patients required PET/CT, contrast-enhanced CT (CECT) and bone marrow biopsy (BMB) at enrolment and end of treatment (EOT). Baseline (BL) data for PET/CT (BLPET/CT), CECT and BMB were compared. Response by CECT and PET/CT was correlated with outcomes. BLPET/CT data were available for 82/84; 98% (80/82) had FDG-avid disease. BLPET/CT altered disease stage in 43% and identified additional extranodal sites (most frequently bone marrow/bone n = 7) in 25% versus CECT. Concordance of BLPET/CT with BMB for marrow involvement was 72.6%, with discordant results for n = 20. Ten patients with biopsy-proven marrow infiltration had a PET/CT-negative marrow. However, BLPET/CT detected marrow involvement in patients with a negative BMB (n = 10), predominantly cases with focal uptake (7/10). At EOT, a negative PET/CT (vs. positive) was associated with superior 2-year progression-free survival (PFS) of 55% (95% CI: 38%-70%) versus 29% (95% CI: 12%-48%) [HR 0.45 (95% CI: 0.23-0.88), p = 0.021], respectively, which remained independently prognostic. Our findings indicate that PET/CT should be incorporated as a standard of care in the management of PTCL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gleeson M, Gonzalez Arias C, Cunningham D, et al. The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial. Br J Haematol. 2025. PMID: 40419413. doi:10.1111/bjh.20160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。